# Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

Study · id `cardio:ct-nct01215955` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01215955](<https://clinicaltrials.gov/study/NCT01215955>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01215955

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1117 participants.

## Technical summary

Registry record NCT01215955. Randomized; no masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2014-02-27.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1117 participants (enrolled count; ClinicalTrials.gov record NCT01215955, source copy `cardio:ctgov-nct01215955-2014-04-23`, retrieved 2026-10-26)
- Start date: 2010-12 (registry gives no type) (ClinicalTrials.gov record NCT01215955, source copy `cardio:ctgov-nct01215955-2014-04-23`, retrieved 2026-10-26)
- Primary completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01215955, source copy `cardio:ctgov-nct01215955-2014-04-23`, retrieved 2026-10-26)
- Completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01215955, source copy `cardio:ctgov-nct01215955-2014-04-23`, retrieved 2026-10-26)
- Results first posted: 2014-02-27 (ClinicalTrials.gov record NCT01215955, source copy `cardio:ctgov-nct01215955-2014-04-23`, retrieved 2026-10-26)
- Countries: United States; Argentina; Austria; Brazil; Canada; Croatia; Denmark; France; Lithuania; Mexico; Poland; Puerto Rico; Romania; Russia; South Africa (ClinicalTrials.gov record NCT01215955, source copy `cardio:ctgov-nct01215955-2014-04-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01215955-2014-04-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
- Acronym: AUTONOMY
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin lispro
- Intervention (Drug): Glargine
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 6331be4891c1469d6a81731d3295c69e3a32e5b4a6d2531fc18bbc3cb995b5f0
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
